Skip to main content
OpenTrials
Recruiting

NCT Number: NCT06932302

At-Home Neuromodulation for Female Sexual Dysfunction

This pilot study investigates the regular use of non-invasive dorsal genital nerve stimulation (DGS) for the treatment of female sexual dysfunction (FSD). The researchers aim to determine whether subjects with FSD can correctly follow an at-home treatment regimen and to demonstrate that DGS can improve FSD arousal symptoms in premenopausal and postmenopausal women. Some subjects will use a smart vibrator for comparison to DGS.

Recruiting

Interested in participating?

Request Info

Key information

Conditions

Female Sexual Dysfunction

Age range

18 year–85 year

Sex eligibility

Female

Study type

Interventional

Phase

Not applicable

Primary location

University of Michigan

Ann Arbor, Michigan, 48109, United States

Location status: Recruiting

Location contact

Priyanka Gupta, MD

SUB_INVESTIGATOR

Tim Bruns, PhD

PRINCIPAL_INVESTIGATOR

Yike Liu

CONTACT

[email protected]

734-647-8568

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Capable of speaking and understanding English.
  • Able to comprehend the clinical study procedures and provide informed consent.
  • Identified as having female sexual dysfunction with a Female Sexual Function Index (FSFI) score of 26.55 or less and a score of 3 or less on one or more of the FSFI subdomains of lubrication, arousal, and orgasm.
  • Willing and able to adhere to the study protocol
  • Able to attend experimental sessions at Michigan Medicine at both the start and conclusion of the study.

Exclusion criteria

  • Not currently sexually active.
  • Pregnant or planning to get pregnant during the study period.
  • History of a neurological disorder or impairments affecting pelvic organ function, including diagnosed with dorsal genital nerve damage, lower motor dysfunction, or other related conditions.
  • Implanted with a neurostimulator for bladder or bowel function.
  • Have a skin condition that would predispose them to sensitivity to the stimulation electrodes.
  • Female sexual dysfunction limited solely to low desire, without issues in lubrication, arousal, or orgasm.
  • Clinically diagnosed bladder dysfunction, pelvic pain, or other pelvic organ symptoms; or a score of 8 or higher on the American Urological Association Symptom Index (AUASI).
  • Unable or unwilling to adhere to the study protocol
  • Simultaneously participating in another research study that may affect the results of this study.

Treatment and study plan

Electrical Stimulation

Device

Electrical stimulation of the dorsal genital nerve will be accomplished using the UCon system and patch electrodes developed by InnoCon. The UCon system includes a programmable control unit; leads that connect to the control unit and electrodes; a silicone surface electrode; a reference electrode; and a remote control for quick on and off toggling of stimulation.

Other names: UCon patch system

Smart vibrator

Device

Subjects will use a smart vibrator at home twice a week during the study. The Lioness smart vibrator records physiological responses during use.

Primary outcomes

  1. Number of dorsal genital nerve stimulation (DGS) sessions performed

    Time frame: Approximately day 22

  2. Number of related adverse events

    Time frame: Up to week 9

    Study-related AEs include incidents such as device zapping, skin irritation, back cramps, or falls due to sitting for 30 minutes of stimulation.

Secondary outcomes

  1. Change in Female Sexual Function Index (FSFI) total scores

    Time frame: Baseline and approximately day 22

    The FSFI is a 19-question survey assessing sexual function in 6 different domains (desire, arousal, lubrication, orgasm, satisfaction, and pain). Each question asks subjects to rate an aspect of their sexual function on a scale from 0 or 1 to 5, depending on the question. The total score for each subdomain is multiplied by a factor so that the maximum score is 6. The total score is out of 36, with the cutoff score for overall dysfunction being 26.55. Subdomain scores of 3 or less indicate dysfunction in the respective subdomain. The FSFI will be conducted before the first study visit and again within one week after completion of the at-home stimulation period in order to see if scores have changed over the course of the treatment.

  2. The Patient Global Impression of Change (PGIC) survey score

    Time frame: Up to week 9

    The Patient Global Impression of Change (PGIC) is a 1-question survey asking patients to describe the change in their condition with a number from 1 to 7. Each number is paired with a description, where 1 represents "No change (or condition is worse)" and 7 represents "A great deal better, and a considerable improvement that has made all the difference". The PGIC will be administered within one week after completion of at-home stimulation, and again 1 month later in order to assess the patient's perception of their change in symptoms.

Study contacts

Contact information is provided by the study sponsor or research team.

Tim Bruns, PhD

CONTACT

[email protected]

734-647-8727

Yike Liu

CONTACT

[email protected]

734-647-8568

Sponsors and collaborators

Lead sponsor

University of Michigan

Other

Registry information

Important dates

Study start
2025
Primary completion
2027
Study completion
2027
First posted
Apr 17, 2025
Registry last updated
Dec 23, 2025

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.